PUBLISHER: The Business Research Company | PRODUCT CODE: 1948336
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948336
Third-generation sequencing technology refers to advanced DNA or RNA sequencing methods capable of reading single molecules in real time, often generating long continuous reads without requiring polymerase chain reaction amplification. Its main objective is to deliver highly accurate and comprehensive genomic and transcriptomic information, allowing the identification of structural variants, epigenetic changes, and complex regions that are difficult to analyze using earlier sequencing methods.
The primary technology types of third-generation sequencing include single-molecule real-time sequencing, transcription-mediated amplification, nanopore sequencing, sequencing by synthesis, and others. Single-molecule real-time sequencing is an advanced approach that monitors DNA synthesis by enzymes in real time, capturing fluorescent signals of each base without template amplification. The workflow consists of sample preparation, sequencing, data analysis, and data storage or management, with applications in genomics, transcriptomics, epigenomics, metagenomics, personalized medicine, and synthetic biology. These methods are used by end users such as academic institutions, clinical laboratories, pharmaceutical and biotechnology companies, research organizations, and government or non-profit institutions.
Tariffs have increased costs for imported sequencing instruments, flow cells, and reagents used in third-generation sequencing. North America and Asia-pacific are most affected. Research and clinical genomics segments face procurement challenges, while tariffs are driving regional manufacturing and reagent localization.
The third-generation sequencing technology market research report is one of a series of new reports from The Business Research Company that provides third-generation sequencing technology market statistics, including third-generation sequencing technology industry global market size, regional shares, competitors with a third-generation sequencing technology market share, detailed third-generation sequencing technology market segments, market trends and opportunities, and any further data you may need to thrive in the third-generation sequencing technology industry. This third-generation sequencing technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The third-generation sequencing technology market size has grown rapidly in recent years. It will grow from $14 billion in 2025 to $15.96 billion in 2026 at a compound annual growth rate (CAGR) of 14.0%. The growth in the historic period can be attributed to genomics research funding, limitations of short-read sequencing, academic research adoption, rise in rare disease studies, technology innovation.
The third-generation sequencing technology market size is expected to see rapid growth in the next few years. It will grow to $26.71 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to precision medicine expansion, clinical diagnostics adoption, reduction in sequencing costs, integration with ai analytics, population genomics initiatives. Major trends in the forecast period include long-read sequencing technologies, real-time dna sequencing, clinical genomics adoption, single-molecule sequencing, portable sequencing platforms.
The rise in the use of personalized medicine is anticipated to drive the expansion of the third-generation sequencing technology market in the future. Personalized medicine is an approach that customizes treatments and preventive measures based on a person's genetic makeup, lifestyle, and environment. The growing popularity of this approach is mainly attributed to advances in genomics, which allow for accurate identification of genetic differences and more precise treatments. Third-generation sequencing technology supports personalized medicine by providing long-read, high-precision genomic data that aids in identifying genetic variations. This technology contributes to personalized treatment plans by offering in-depth insights into individual genomes, thereby improving clinical outcomes and advancing precision healthcare. For example, in February 2024, the Personalized Medicine Coalition (PMC), a nonprofit organization in the U.S., reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. This increasing adoption of personalized medicine is a key factor in the growth of the third-generation sequencing technology market.
Leading players in the third-generation sequencing technology market are working on the development of advanced sequencing platforms, such as ultra-rapid and scalable sequencing systems, to enhance research efficiency, improve clinical application, and lower turnaround times and costs. These sequencing systems are innovative technologies that offer high-throughput, real-time genomic analysis with remarkable speed and accuracy, enabling detailed genomic profiling for a wide range of applications. For example, in February 2025, Roche Holding AG, a pharmaceutical company based in Switzerland, introduced Sequencing by Expansion (SBX) technology. This fully integrated next-generation sequencing system uses a patented biochemical process to convert DNA or RNA sequences into measurable surrogate polymers called Xpandomers, allowing for precise single-molecule nanopore sequencing. The SBX platform is equipped with ultra-rapid, scalable sequencing features and automated data analysis, producing whole-genome sequencing results in a matter of hours rather than days without requiring extensive manual work.
In August 2023, PacBio, a U.S.-based company known for delivering highly accurate, high-quality sequencing solutions, acquired Apton Biosystems in a deal valued at up to $110 million. Through this acquisition, PacBio intends to speed up the development of a high-throughput short-read sequencing platform by combining its Sequencing by Binding (SBB) chemistry with Apton's sophisticated optics and image-processing technologies. Apton Biosystems is a U.S.-based firm focused on developing a high-throughput short-read sequencer capable of sequencing billions of DNA clusters on a single flow cell.
Major companies operating in the third-generation sequencing technology market are Oxford Nanopore Technologies, Pacific Biosciences, Quantapore, Ultima Genomics, BGI Genomics, MGI Tech, Complete Genomics, Stratos Genomics, VisiGen Biotechnologies, Helicos Biosciences, Genia Technologies, Electronic Bio Sciences, Quantum Biosystems, Base4 Innovation, Nabsys, Chronix Biomedical, Roche, Nanopore Diagnostics, GenapSys, SomaLogic
North America was the largest region in the third-generation sequencing technology market in 2025. The regions covered in the third-generation sequencing technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the third-generation sequencing technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The third-generation sequencing technology market consists of revenues earned by entities by providing services such as whole genome sequencing, transcriptome sequencing, epigenetic analysis, de novo genome assembly, single-cell sequencing, and structural variant detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The third-generation sequencing technology market also includes sales of sequencing instruments, reagents, flow cells, sample preparation kits, nanopore devices, optical mapping systems, microfluidic chips, and sample preparation instruments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Third-Generation Sequencing Technology Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses third-generation sequencing technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for third-generation sequencing technology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The third-generation sequencing technology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.